Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
The new lineup includes CereTom Elite, OmniTom Elite, OmniTom Elite PCD, and BodyTom 32/64
Athena is also exploring the use of this technology for expanded carrier screening
Vasograin Plus represents a major advancement in the treatment of migraine
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Subscribe To Our Newsletter & Stay Updated